Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Short Communication Volume 4 Issue 3

Are We Any Closer for a Safe Vaccine to be Launched-Experience of Phase 3 Trials of Certain Vaccines with Immune Responses in COVID-19 with a 3rs Wave in Most Countries Escalating SARS-CoV2-Patients

Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3

1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: October 31, 2020; Published: February 10, 2021

×

  Earlier having reviewed structure and treatment (Figure 1) options of COVID-19 secondary to SARS-COV2 [1-5], still the pandemic instead of getting controlled is on a rise and urgent need of a vaccine is required with the 3rd wave having attacked the world, here we discuss important points regards to getting insight of disease pathogenesis along with advantage of bridge therapies, like hyperimmune globulin along with convalescent human plasma besides developing vaccines, antivirals and monoclonal abs. Just 11 months back knowledge was not there. Here we sum up phase 3 trial of vaccines-status.

×

References

  1. Kulvinder Kochar Kaur., et al. “A Comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel corona virus syndrome –COVID-19”. Iberoamerican Journal of Medicine 2 (2020): 110-123.
  2. Kulvinder Kochar Kaur. “Editorial –Maximum possible efforts by which we will win over this Deadly Pandemic of COVID-19”. Acta Scientific Microbiology6 (2020): 01-03.
  3. Kulvinder Kochar Kaur., et al. “An Update on COVID19 from Etiopathogenesis, to role in male infertility, Pregnancy Lactation, and Regarding treatment”. Journal of Gynecology1 (2020): 000200.
  4. Kulvinder Kochar Kaur., et al. “Editorial-An update on management of severe COVID19 presenting with Cytokine Release Syndrome responsible for most mortalities in COVID19”. Acta Scientific Microbiology8 (2020): 01-06.
  5. Kulvinder Kochar Kaur., et al. “An update on the place of ART with SARS CoV2-around and influence on Both Reproduction, transmission possibilities to, Progeny, Partners And Staff –What is the Answer” Keynote Speech In the Webinar during 5th International Conference on Obstetrics And Gynecology heldon 22-9-2020.
  6. Poland GA., et al. “SARS-COV2 immunity: review and applications to phase 3 vaccine candidates”. Lancet (2020).
  7. Simran preet Kaur and Vandana Gupta. “COVID19 Vaccines: a comprehensive status report”. Elsevier online (2020).
  8. Chung YH, ., et al. “COVID19 Vaccines frontrunneres and their nanotechnology design”. ACS Nano (2020).
  9. van Doremalen N., et al. “ChAdOx1 nCoV-19vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques”. bioRxiv (2020).
  10. Folegatti PM., et al. “Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”. Lancet 396 (2020): 467-478.
  11. Corbett KS., et al. “Evaluation of the mRNA-1273vaccine against SARS-CoV-2 in nonhuman primates”. The New England Journal of Medicine (2020).
  12. Jackson LA., et al. “An mRNA vaccineagainst SARS-CoV-2—preliminary report”. The New England Journal of Medicine (2020).
  13. Mulligan MJ., et al. “Phase 1/2 study ofCOVID-19 RNA vaccine BNT162b1 in adults”. Nature (2020).
  14. Loftus P. For COVID-19 vaccine, J&J plans 60,000-subject pivotaltrial (2020).
  15. Mercado NB., et al. “Single-shot Ad26vaccine protects against SARS-CoV-2 in rhesus macaques”. Nature (2020).
  16. Logunov DY., et al. “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologou prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (2020): 887-897.
  17. Bucci E. Note of concern. (2020).

 

×

Citation

Citation: Kulvinder Kochar Kaur., et al. “Are We Any Closer for a Safe Vaccine to be Launched-Experience of Phase 3 Trials of Certain Vaccines with Immune Responses in COVID-19 with a 3rs Wave in Most Countries Escalating SARS-CoV2-Patients". Acta Scientific Microbiology 4.3 (2021): 30-36.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.172

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US